PROTHERICS AND ASTRAZENECA ANNOUNCE LATE STAGE LICENSING AGREEMENT ON CYTOFAB FOR TREATMENT OF SEPSIS

A A

Protherics, the biopharmaceutical company focused on critical care and oncology, today announces an agreement with AstraZeneca for the global development and commercialisation of Protherics' anti-sepsis product CytoFab. CytoFab is currently being prepared for a single phase III registration study in severe sepsis in line with guidance received at an end of phase II meeting with the US Food and Drug Administration (FDA).
Market Wire